Enfusion Stock Beneish M Score
| ENFN Stock | USD 9.67 0.03 0.31% |
Enfusion | Beneish M Score |
At this time, it appears that Enfusion is a possible manipulator. The earnings manipulation may begin if Enfusion's top management creates an artificial sense of financial success, forcing the stock price to be traded at a high price-earnings multiple than it should be. In general, excessive earnings management by Enfusion executives may lead to removing some of the operating profits from subsequent periods to inflate earnings in the following periods. This way, the manipulation of Enfusion's earnings can lead to misrepresentations of actual financial condition, taking the otherwise loyal stakeholders on to the path of questionable ethical practices and plain fraud.
10.95
Beneish M Score - Possible Manipulator
Enfusion Beneish M-Score Indicator Trends
The cure to earnings manipulation is the transparency of financial reporting. It will typically remove the temptation of the top executives to inflate earnings (i.e., to promote the idea of 'winning at any cost'). Because a healthy internal audit department can enhance transparency, the board should promote the auditors' access to all the record-keeping systems across the enterprise. For example, if Enfusion's auditors report directly to the board (not management), the managers will be reluctant to manipulate simply due to the fear of punishment. On the other hand, the auditors will be free to investigate the ledgers properly because they know that the board has their back.
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Net Receivables | 20.5 M | 28.1 M |
|
| |||||
| Total Revenue | 126.5 M | 174.5 M |
|
| |||||
| Total Assets | 88.2 M | 109 M |
|
| |||||
| Total Current Assets | 66.3 M | 69.9 M |
|
| |||||
| Non Current Assets Total | 21.9 M | 39.1 M |
|
| |||||
| Property Plant Equipment | 12 M | 18.1 M |
|
| |||||
| Depreciation And Amortization | 4.7 M | 8.6 M |
|
| |||||
| Selling General Administrative | 74 M | 64.6 M |
|
| |||||
| Total Current Liabilities | 14.2 M | 20.3 M |
|
| |||||
| Non Current Liabilities Total | 10.6 M | 11.2 M |
|
| |||||
| Short Term Debt | 3 M | 4.3 M |
|
| |||||
| Long Term Debt | 67.9 M | 110.5 M |
|
| |||||
| Gross Profit Margin | 0.77 | 0.6697 |
|
|
Enfusion Beneish M-Score Driver Matrix
One of the toughest challenges investors face today is learning how to quickly synthesize historical financial statements and information provided by the company, SEC reporting, and various external parties in order to detect the potential manipulation of earnings. Understanding the correlation between Enfusion's different financial indicators related to revenue, expenses, operating profit, and net earnings helps investors identify and prioritize their investing strategies towards Enfusion in a much-optimized way. Analyzing correlations between earnings drivers directly associated with dollar figures is the most effective way to find Enfusion's degree of accounting gimmicks and manipulations.
Click cells to compare fundamentals
About Enfusion Beneish M Score
M-Score is one of many grading techniques for value stocks. It was developed by Professor M. Daniel Beneish of the Kelley School of Business at Indiana University and published in 1999 under the paper titled The Detection of Earnings Manipulation. The Beneish score is a multi-factor model that utilizes financial identifiers to compile eight variables used to classify whether a company has manipulated its reported earnings. The variables are built from the officially filed financial statements to create a final score call 'M Score.' The score helps to identify companies that are likely to manipulate their profits if they show deteriorating gross margins, operating expenses, and leverage against growing revenue.
Depreciation And Amortization |
|
Enfusion ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Enfusion's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Enfusion's managers, analysts, and investors.Environmental | Governance | Social |
About Enfusion Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Enfusion's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Enfusion using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Enfusion based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Enfusion Piotroski F Score and Enfusion Altman Z Score analysis. To learn how to invest in Enfusion Stock, please use our How to Invest in Enfusion guide.Note that the Enfusion information on this page should be used as a complementary analysis to other Enfusion's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Complementary Tools for Enfusion Stock analysis
When running Enfusion's price analysis, check to measure Enfusion's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Enfusion is operating at the current time. Most of Enfusion's value examination focuses on studying past and present price action to predict the probability of Enfusion's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Enfusion's price. Additionally, you may evaluate how the addition of Enfusion to your portfolios can decrease your overall portfolio volatility.
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance |
Is Enfusion's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Enfusion. If investors know Enfusion will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Enfusion listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.94) | Earnings Share 0.02 | Revenue Per Share 2.055 | Quarterly Revenue Growth 0.173 | Return On Assets 0.0331 |
The market value of Enfusion is measured differently than its book value, which is the value of Enfusion that is recorded on the company's balance sheet. Investors also form their own opinion of Enfusion's value that differs from its market value or its book value, called intrinsic value, which is Enfusion's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Enfusion's market value can be influenced by many factors that don't directly affect Enfusion's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Enfusion's value and its price as these two are different measures arrived at by different means. Investors typically determine if Enfusion is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Enfusion's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.